A Clinical Trial of MK-4082 in Healthy Participants (MK-4082-005)

Part of paid clinical trials in Anaheim, California.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07697625
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • MK-4082 — DRUG
    Oral administration
  • Diltiazem — DRUG
    Oral administration
  • Rescue medication — DRUG
    All participants will receive ondansetron as a rescue medication. Ondansetron is a medication used to prevent nausea or vomiting.

Study Details

Researchers are looking for new weight loss medicines for people with higher body weight. The trial medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a trial medicine to participants with a health condition, researchers first do trials in healthy participants to find a safe dose level (amount) of the trial medicine. The goal of this study is to learn what happens to MK-4082 in a person's body over time. Researchers will compare what happens to levels of MK-4082 in people's blood when it is taken alone (Part 1, Period 1 and Part 2) and in combination with (Part 1, Period 2) another medicine called diltiazem. Researchers also want to learn about the safety of MK-4082 taken with and without diltiazem and if people tolerate them.

Key Dates

First listed
Jul 13, 2026
Start date
Jul 20, 2026
Status verified
Aug 2026
Primary completion
Sep 28, 2026
Completion
Sep 28, 2026

Study Design

Enrollment
28 participants (estimated)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: MK-4082
    Participants will move sequentially through 2 periods in Part 1. In Period 1, participants will receive a single oral dose of MK-4082 on Day 1. In Period 2, participants will receive a single oral dose of MK-4082 on Day 1 plus oral diltiazem for multiple days. In Part 2 participants receive a single dose of MK-4082 or placebo.

Primary Outcome Measure

Part 1: Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-∞) of MK-4082 [ Time Frame: At designated timepoints (up to approximately 1 week postdose) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Anaheim Clinical Trials ( Site 0001)AnaheimCalifornia92801
Study Coordinator
714-774-7777

Find similar trials in Anaheim, CA

By research site
Anaheim Clinical Trials· Anaheim, CA

Related Studies